According to some preliminary results, these techniques could be able to differentiate in vivo MSA- from PD-α -synuclein strains when assessed in the cerebrospinal fluid (CSF) of affected subjects, bearing a great potential for the development of MSA fluid biomarkers and for improving the early and differential diagnosis across α-synucleinopathies (Fellner et al. 2020; Shahnawaz et al. 2020). The gene discussed is SNCA; the disease is Parkinson disease.